A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

This trial tests a new drug called GNC-035 for patients with relapsed or refractory non-Hodgkin's lymphoma (a type of blood cancer) and other blood cancers that have stopped responding to prior treatments. **You may be eligible if...** - You are 18–75 years old - You have a confirmed diagnosis of relapsed or refractory non-Hodgkin's lymphoma - You have already tried at least one standard treatment and it stopped working - Your cancer has at least one measurable tumor according to standard criteria (Lugano) - Your general health is adequate (ECOG performance status 0–2) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You are younger than 18 or older than 75 - Your cancer has not been previously treated - You do not have measurable disease on imaging - Your organ function is significantly impaired Talk to your doctor to see if this trial is right for you.